3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Polycystic Ovary Syndrome
14
Breast Neoplasms
11
Prostatic Neoplasms
9
Obesity
7
Insulin Resistance
6
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
4
Colorectal Neoplasms
4
Motor Activity
3
Adenocarcinoma of Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Neoplasms
2
Menstruation Disturbances
2
Lymphoma, Large B-Cell, Diffuse
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Diabetes Mellitus
2
Weight Loss
1
Urothelial Cancer
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Smoldering Multiple Myeloma
1
Rectal Neoplasms
1
Prediabetic State
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Overweight
1
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
1
Non-alcoholic Fatty Liver Disease
1
Interventions
Rituximab
173
Cyclophosphamide
156
Vincristine
72
fludarabine phosphate
71
Etoposide
68
Doxorubicin
68
Prednisone
66
Filgrastim
58
Methotrexate
52
Cytarabine
51
fludarabine
49
Melphalan
48
Busulfan
47
Tacrolimus
41
Whole-Body Irradiation
39
Mycophenolic Acid
39
Granulocyte Colony-Stimulating Factor
37
Antilymphocyte Serum
31
Peripheral Blood Stem Cell Transplantation
30
Radiotherapy
27
Lenalidomide
25
Dexamethasone
25
Carmustine
23
Stem Cell Transplantation
22
Cyclosporine
22
Bortezomib
22
Gemcitabine
20
Bendamustine Hydrochloride
20
ibritumomab tiuxetan
19
Alemtuzumab
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma
×
Metformin
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts